Aardvark Therapeutics, Inc. (AARD) Price & Analysis

Compare

67 Followers

AARD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.88 - $19.58

Previous CloseN/A

VolumeN/A

Average Volume (3M)200.23K

Market Cap

$369.93M

Enterprise Value$152.11M

Total Cash (Recent Filing)$141.82M

Total Debt (Recent Filing)$645.00K

Price to Earnings (P/E)―

Beta1.62

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding21,696,894

10 Day Avg. Volume144,829

30 Day Avg. Volume200,227

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.41

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.65K

Enterprise Value/Ebitda-3.73

Forecast

1Y Price Target

$31.43

Price Target Upside84.34% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe cash position of $141.8M ensures financial stability for Aardvark, providing a runway into 2027.

Investment AppealUndervalued status relative to remaining listed peers indicates a potentially compelling buying opportunity.

Market OpportunityThe PWS market is large, and even gaining a minority share presents a meaningful opportunity for ARD-101, with potential upside due to market size and Vykat's success.

Bears Say

Clinical Data ImperfectionsBoth the clinical data and the mechanism/biology behind ARD-101 are considered imperfect and present real risk.

Clinical Trial RiskDespite optimism, there is a risk that the trial could fail simply by chance due to the challenging nature of Prader-Willi Syndrome.

Aardvark Therapeutics, Inc. News

Aardvark Therapeutics announces FDA alignment on HERO trial protocol amendment

Aardvark Therapeutics (AARD) announces alignment with the U.S. Food and Drug Administration on a protocol amendment to the...

30m ago

AARD

Aardvark Therapeutics initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Aardvark Therapeutics (AARD) with a Buy rating and $33 price target Aardvark is a...

7d ago

AARD

Aardvark Therapeutics initiated with a Buy at Stifel

Stifel initiated coverage of Aardvark Therapeutics (AARD) with a Buy rating and $24 price target The firm believes...

9d ago

AARD

Promising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark Therapeutics

Aardvark Therapeutics, Inc. (AARD) has received a new Buy rating, initiated by JonesTrading analyst, Catherine Novack. Catherine Novack’s...

7d ago

AARD

Buy Rating for Aardvark Therapeutics: ARD-101’s Potential in Prader-Willi Syndrome Treatment

Aardvark Therapeutics, Inc. (AARD) has received a new Buy rating, initiated by Stifel Nicolaus analyst, James Condulis. James...

9d ago

AARD

Aardvark Therapeutics: Undervalued Opportunity in Obesity Treatment Market with Promising Pipeline and Upcoming Catalysts

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aardvark Therapeutics, Inc.,...

15d ago

AARD

Aardvark Therapeutics reports inducement grants under Nasdaq listing rule

Aardvark Therapeutics (AARD) announced that on August 28, 2025, two new employees were granted inducement awards consisting of...

1M ago

AARD

Aardvark Therapeutics Updates Corporate Presentation on Strategy

Aardvark Therapeutics, Inc. ( ($AARD) ) has provided an announcement. On September 2, 2025, Aardvark Therapeutics, Inc. updated...

1M ago

AARD

Aardvark Therapeutics price target lowered to $25 from $26 at BofA

BofA analyst Tim Anderson lowered the firm’s price target on Aardvark Therapeutics (AARD) to $25 from $26 and...

1M ago

AARD

Aardvark Therapeutics Advances Clinical Trials and Financials

Aardvark Therapeutics, Inc. ( ($AARD) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

AARD

Aardvark Therapeutics price target lowered to $19 from $20 at RBC Capital

RBC Capital lowered the firm’s price target on Aardvark Therapeutics (AARD) to $19 from $20 and keeps an...

2M ago

AARD

Aardvark Therapeutics reports Q2 EPS (66c), consensus (60c)

“Aardvark has made significant progress across our pipeline, and we are well-positioned to unlock the full potential of...

2M ago

AARD

Buy Rating for Aardvark Therapeutics, Inc. Driven by Promising ARD-201 Obesity Treatment Potential

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aardvark Therapeutics, Inc. today and set a price...

2M ago

AARD

Aardvark Therapeutics Reveals Promising Preclinical Data for ARD-201

Aardvark Therapeutics, Inc. ( ($AARD) ) has shared an announcement. On August 12, 2025, Aardvark Therapeutics announced promising...

2M ago

AARD

AARD FAQ

What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?

Aardvark Therapeutics, Inc. lowest stock price was $4.88 and its highest was $19.58 in the past 12 months.

What is Aardvark Therapeutics, Inc.’s market cap?

Aardvark Therapeutics, Inc.’s market cap is $369.93M.

When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Aardvark Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Aardvark Therapeutics, Inc. overvalued?

According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aardvark Therapeutics, Inc. pay dividends?

Aardvark Therapeutics, Inc. does not currently pay dividends.

What is Aardvark Therapeutics, Inc.’s EPS estimate?

Aardvark Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aardvark Therapeutics, Inc. have?

Aardvark Therapeutics, Inc. has 21,696,894 shares outstanding.

What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?

Currently, no hedge funds are holding shares in AARD

Aardvark Therapeutics, Inc. Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

635.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. (AARD) is a biotechnology company focused on developing innovative therapies for metabolic and inflammatory diseases. The company specializes in creating and advancing novel treatments aimed at addressing unmet medical needs in these sectors. Its core products include proprietary drug candidates designed to modulate metabolic pathways and reduce inflammation, ultimately improving patient outcomes and quality of life.

Aardvark Therapeutics, Inc. (AARD) Earnings & Revenues

Historic Earnings Reports

AARD Stock 12 Month Forecast

Average Price Target

$31.43

▲(84.34% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","18":"$18","29":"$29","40":"$40","51":"$51"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,18,29,40,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.86,12.024615384615384,15.189230769230768,18.353846153846156,21.518461538461537,24.683076923076925,27.84769230769231,31.012307692307694,34.176923076923075,37.34153846153846,40.50615384615385,43.67076923076923,46.83538461538462,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.86,10.596153846153845,12.332307692307692,14.068461538461538,15.804615384615385,17.54076923076923,19.276923076923076,21.013076923076923,22.74923076923077,24.485384615384614,26.22153846153846,27.95769230769231,29.693846153846152,{"y":31.43,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.86,9.639999999999999,10.42,11.2,11.98,12.76,13.54,14.32,15.1,15.879999999999999,16.66,17.439999999999998,18.22,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.3,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.3,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.73,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.33,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >